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We show that interferon-induced transmembrane protein 1 (IFITM-1), IFITM-2, and IFITM-3 exhibit a broad spectrum of anti-
viral activity against several members of the Bunyaviridae family, including Rift Valley fever virus (RVFV), La Crosse virus, An-
des virus, and Hantaan virus, all of which can cause severe disease in humans and animals. We found that RVFV was restricted
by IFITM-2 and -3 but not by IFITM-1, whereas the remaining viruses were equally restricted by all IFITMs. Indeed, at low doses
of alpha interferon (IFN-), IFITM-2 and -3 mediated more than half of the antiviral activity of IFN- against RVFV. IFITM-2
and -3 restricted RVFV infection mostly by preventing virus membrane fusion with endosomes, while they had no effect on vi-
rion attachment to cells, endocytosis, or viral replication kinetics. We found that large fractions of IFITM-2 and IFITM-3 occupy
vesicular compartments that are distinct from the vesicles coated by IFITM-1. In addition, although overexpression of all
IFITMs expanded vesicular and acidified compartments within cells, there were marked phenotypic differences among the vesic-
ular compartments occupied by IFITMs. Collectively, our data provide new insights into the possible mechanisms by which the
IFITM family members restrict distinct viruses.
In response to viral infections, nearly all vertebrate cells producetype I interferons (IFNs). This class of cytokines can induce ex-
pression of hundreds of IFN-stimulated genes (ISGs), thereby es-
tablishing an antiviral state in neighboring cells (1). Conse-
quently, an adaptive immune response is established and viral
spread throughout the organism is diminished (reviewed in refer-
ence 2). Although there aremany known ISGs, the antiviralmech-
anisms of only a few have been well characterized (reviewed in
reference 3). Recent studies have identified the novel antiviral ac-
tivity of a family of small ISGs known as interferon-induced trans-
membrane proteins (IFITMs). In humans, the IFITM family is
composed of four functional genes, three of which (IFITM-1, -2,
and -3) are ubiquitously expressed and induced by both type I and
type II IFNs (4–6), while expression of the fourth member
(IFITM-5) is limited to osteoblasts (7). IFITMs have been shown
to restrict specific enveloped viruses, including influenza A virus
(FLUAV) (8), severe acute respiratory syndrome coronavirus
(SARS-CoV), Ebola virus (EBOV), and Marburg virus (MARV)
(9), flaviviruses (including dengue virus types 1 and 2 [DENV-
1/2] and West Nile virus [WNV]) (9, 10), HIV-1 (11), and vesic-
ular stomatitis Indiana virus (VSIV) (12). In contrast, these pro-
teins had no effect on murine leukemia virus (MLV) and
arenaviruses, such as Lassa virus (LASV) and Machupo virus
(MACV) (8, 9). Furthermore, in vivo studies using IFITM-3-
knockout mice, as well as humans possessing specific IFITM-3
gene mutations, have demonstrated that these individuals are
more susceptible to disease caused by influenza A virus (13, 14).
The molecular mechanisms by which IFITMs inhibit infection
are still unclear, but accumulating evidence suggests that IFITM-3
alters the membranes of the vesicular compartments, such that
virion-host membrane fusion is prevented and the endocytosed
virions thereby remain trapped within the vesicles. For example,
IFITM-3 did not inhibit the binding or entry of influenza A virus
(8, 9, 15) or HIV-1 (11) but did prevent the release of ribonucle-
oprotein complex (RNP) into the cytoplasm. Additionally,
IFITM-3 restriction of VSIV could be overcome by introducing
viral genomic RNA directly into the cytoplasm (12). IFITM-3 has
been shown to partially reside in late endosomal and lysosomal
compartments (9, 15, 16), and its overexpression expands these
acidified compartments (including Rab-5-, Rab-7-, and LAMP-
1-coated vesicles) (15). Previous work has shown that IFITMs
possess differential antiviral activities against diverse viruses.
IFITM-3 was most potent in resisting FLUAV, VSIV, WNV, and
DENV infections, while IFITM-1 restriction of WNV and DENV
infections was cell type dependent (9, 10, 12). However, IFITM-1,
-2, and -3 all restrict HIV-1, FLUAV, Ebola virus, and Marburg
virus infections, but the efficiency of inhibition depended on the
host cell type (9, 11, 15). The mechanism behind the differential
sensitivity of viruses to these proteins is not understood.
Rift Valley fever (RVF) virus (RVFV) is an emerging pathogen
capable of causing serious epidemics among livestock and hu-
mans. RVFVwas first described in 1931 (17) in East Africa and has
since caused large eruptive disease throughout Africa and, more
recently, on the Arabian Peninsula (reviewed in references 18 to
20). In domestic ruminants, RVF results in abortion and high
fatality rates, especially among young animals. Although it is typ-
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ically a self-limiting febrile illness in humans, a small percentage of
RVF cases develop severe viral hemorrhagic fever (VHF), neuro-
logical disorders, and/or blindness (21, 22). Attenuated RVFV
vaccine strains have been developed for prophylaxis (23–26), but
to date there are no licensed drugs or vaccines approved in the
United States. A better understanding of the life cycle of RVFV at
themolecular level will undoubtedly help to develop effective vac-
cines and antivirals.
RVFV, a phlebovirus of the family Bunyaviridae, forms spher-
ical enveloped virions that contain three single-stranded genomic
RNAs (L, M, and S segments) of negative polarity that are encap-
sidated by nucleoprotein (NP) (27, 28). Although the mechanism
of RVF particle entry into host cells is not completely understood,
it has been shown that the envelope glycoproteins (Gn andGc) on
the surface of the virion regulate cell entry via binding to an un-
known cell surface receptor (29–31). The endocytosed virions fur-
ther undergo a low-pH-dependent membrane fusion (32) that
leads to the release of the RNP into the cytoplasm. This mode of
entry presents an attractive target for IFITM-mediated restriction.
Furthermore, RVFV infection is highly sensitive to type I IFN,
such that treating cells even with low doses of alpha IFN (IFN-)
prior to infection inhibits viral replication (29, 33). Therefore,
RVFV infection serves as a useful model to explore the antiviral
activity of individual ISGs, such as IFITMs.
In this study, we demonstrate that IFITM-2 and -3 but not
IFITM-1 restrict RVFV infectionmostly by preventing viralmem-
brane fusion with the endosomes during virus entry. We further
show that a large fraction of IFITM-1 resides in a vesicular com-
partment different from that occupied by IFITM-2 or -3. This has
led to our speculation that IFITM-2 and -3 but not IFITM-1 are
present at the sites of RVFVmembrane fusion. Since other mem-
bers of the Bunyaviridae family share a similar entry mechanism,
we hypothesized that bunyaviruses may be restricted by IFITMs,
similar to RVFV. We therefore analyzed IFITM regulation of bu-
nyaviruses, including La Crosse virus (LACV), Hantaan virus
(HTNV), Andes virus (ANDV), and Crimean-Congo hemor-
rhagic fever virus (CCHFV), which are all known to cause serious
disease in animals and humans (reviewed in reference 34). IFITMs
exhibited broad-spectrum antiviral activity against LACV,
HTNV, and ANDV infections but not CCHFV infection. Interest-
ingly, unlike RVFV infection, IFITM-1, -2, and -3 were all able to
prevent LACV,HTNV, andANDV infectionwith similar efficien-
cies. The implications of these findings are discussed.
MATERIALS AND METHODS
Cells, medium supplements, and viruses. HeLa, Vero E6, 293T, and
A549 cells were maintained in Dulbecco’s modified Eagle medium (Life
Technologies) supplementedwith 10% (vol/vol) fetal bovine serum (FBS;
Life Technologies). Vero E6 cell lines stably expressing IFITM proteins
were generated as described previously (9) and were maintained in com-
plete growthmedium supplemented with 4g/ml puromycin (Life Tech-
nologies). Human IFN-2a (catalog no. 11100-1) was purchased from
PBL Interferon Source. RVFV strains ZH548/MP-12 (MP-12) andZH501
were obtained from The Salk Institute, Government Services Division,
and fromMichael Turell (United States ArmyMedical Research Institute
of Infectious Diseases [USAMRIID]), respectively. The RVFV MP-12
strain, derived from virulent strain ZH548 of RVFV, is highly attenuated
by several mutations (35, 36), retains its sensitivity to IFN- (37, 38), and
serves as an alternate model to the virulent RVFV strain that may be
workedwith under biosafety level 2 (BSL-2) laboratory conditions, unlike
the virulent strains, which have to be handled in BSL-3 labs. RVFVZH501
and RVFVMP-12 (passage 1) were propagated in Vero cells, and the virus
from the supernatant was precipitated overnight at 4°C with 5% polyeth-
ylene glycol (molecular weight, 8,000; Sigma) and 2.3%NaCl (Sigma) and
centrifuged at 17,000  g for 2 h. The virus pellet was resuspended in
phosphate-buffered saline (PBS), aliquoted, and stored at 80°C. The
Romero strain of Junín virus (JUNV) was propagated from a USAMRIID
stock whichwas passaged five times in Vero cells. The passage 6 viral stock
used in these experiments was propagated at a multiplicity of infection
(MOI) of 0.01 in Vero cells and harvested on day 4 postinfection in a
supernatant pool supplemented with 10% (vol/vol) FBS, aliquoted, and
frozen at80°C. ANDV, HTNV, and LACV were propagated in Vero E6
cells, and the virus-containing cell culture supernatant from the final pas-
sage was clarified by centrifugation at 12,000  g for 30 min, prior to
aliquoting of the virus and storage at 80°C. CCHFV IbAr10200 was
passaged twice in SW13 cells, twice inHepG2 cells, and twice in CER cells.
The virus-containing cell culture supernatant from the final passage was
clarified by centrifugation at 12,000 g for 30 min, prior to aliquoting of
the virus and storage at80°C. All virus stock titers were determined by
plaque assay, as described below.
Plaque assays. RVFV, JUNV, and LACV yields were determined by a
standard plaque assay, as previously described (39), with minor changes.
Briefly, serial 10-fold dilutions of each specimen were prepared in Eagle
minimal essential medium (EMEM) with 10% (vol/vol) FBS added (Life
Technologies). Two hundred microliters of each dilution was then ad-
sorbed onto triplicate wells of Vero E6 cell monolayers for 1 h at 37°C in a
6-well plate. After 1 h, themonolayerswere overlaidwith 2ml of amixture
of 1 part 1% (wt/vol) agarose and 1 part 2 EMEM, 17 mMHEPES, 8%
(vol/vol) fetal bovine serum, 100 U/ml of penicillin, and 100 g/ml of
streptomycin sulfate (Life Technologies). After an appropriate time of
incubation (3 to 4 days), when cytopathic effects began to appear, each cell
monolayer was stained by adding 2 ml of a secondary overlay identical to
the primary overlay but also containing 0.02% (wt/vol) neutral red
(Sigma). After an additional 24 h of incubation, plaques were enumerated
and viral titers were calculated.
siRNA knockdown. The reverse transfection method and HiPerfect
transfection reagent (Qiagen) were used to transfect HeLa cells in 96-well
plates (8,000 cells per well) with a 15 nM solution of small interfering
RNA (siRNA) targeting human IFITM-1 (catalog no. L-019543-00;
ON-TARGETplus; Thermo Scientific), human IFITM-2 (catalog no.
L-020103-00; ON-TARGETplus; Life Technologies), or human IFITM-3
(siRNA identification no. s195035; Silencer Select; Life Technologies),
with control siRNA (nontargeting siRNA; catalog no. D-001810-04; ON-
TARGETplus; Life Technologies), or with medium containing the trans-
fection reagent alone. One day later, cells were washed with PBS and then
replenishedwith growthmediumcontaining increasing concentrations of
IFN- or withmedium alone for the times indicated for each experiment.
At 48 h posttransfection, cells were infected with RVFV or mock infected
with medium alone. Alternatively, cells were harvested for RNA extrac-
tion to determine the target gene levels by quantitative reverse transcrip-
tase PCR (qRT-PCR) analysis.
Infection assays. All cells used in the study, including HeLa, Vero E6,
A549, or 293T cells, were infected with RVFV strain MP-12 or ZH501,
LACV strainWest Virginia-1997 (a kind gift fromMichael Turell, USAM-
RIID), JUNV strain Romero, HTNV strain 76-118, ANDV strain Chile-
9717869, or CCHFV strain IbAr10200 at the indicated MOIs. Inocula
were removed after 1 h, unless stated otherwise, washed with 1 PBS, and
replacedwith the same amount of freshmedium. Infectionwas allowed to
proceed for a specific duration of time, as described for each experiment.
At the end of the incubation time, culture supernatants were collected to
determine the virus yield by plaque assay or qRT-PCR analysis. Alterna-
tively, cells infected with RVFV, JUNV, ANDV, HTNV, or CCHFV were
fixed in 10% neutral buffered formalin (Val Tech Diagnostics) for 3 days
and processed for immunofluorescence staining for image-based analysis.
qRT-PCR. RVFV RNA yields in the cells were determined by qRT-
PCR using TaqMan-based probe sequences as previously described (40).
Mudhasani et al.
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In brief, total RNA from untreated cells (mock infected) or cells infected
with RVFV were prepared using a MagMax 96 RNA extraction kit (Am-
bion). qRT-PCR assays were performed on an ABI Prism 7900HT se-
quence detection systemwith an RNAUltraSense one-step kit (Life Tech-
nologies) and TaqMan probes (Applied Biosystems) according to the
manufacturers’ instructions. Serial 10-fold dilutions of the assayed virus
(102 to 107 copies) were used as standards. To determine relative levels of
IFITM-1, IFITM-2, and IFITM-3 expression in IFN-- or siRNA-treated
HeLa cells, total RNA was isolated at the indicated time points posttreat-
ment using an RNeasy Plus minikit (Qiagen). Purified RNA was then
measured with a Quant-IT RiboGreen RNA assay kit (Life Technologies).
Fifty nanograms of eachRNAwas used in qRT-PCRassays under the same
conditions described above with IFITM and PPIB TaqMan probes (Ap-
plied Biosystems). The target gene RNA or mRNA expression levels were
normalized to the level of expression of the PPIB housekeeping gene.
Relative expression levels were determined using the comparative thresh-
old cycle (CT) method (41).
Staining of acidified compartments. Vero E6 cells stably expressing
vector alone or IFITMs were incubated with LysoTracker red DND-99 or
LysoTracker green DND-26 (Life Technologies) at 50 nM and 1M con-
centrations, respectively, for 2 h. Cells were washed and replaced with
medium containing Hoechst 33342 to stain nuclei, following which im-
ages were collected at a63 magnification on an Opera confocal reader,
as described below.
Immunofluorescence studies.Formalin-fixed cellswere untreated or,
when indicated, permeabilized with 0.1% Triton X-100 (Sigma)–PBS for
15 min. Samples were then blocked in PBS containing 3% bovine serum
albumin for 1 h, and proteins were stained with antibodies. The murine
monoclonal antibody 4D4 detects the Gn portion of the glycoprotein of
RVFV, and for rest of the report it is referred to as GP. Themurinemono-
clonal antibody R3-ID8-1-1was used for visualizing the expression of the
NP of RVFV. JUNV-infected cells were stained with the murine mono-
clonal antibody MA03-BE06 to detect expression of NP. ANDV and
HTNV infectionwasmeasured by staining for theirNprotein using rabbit
polyclonal antiserum specific to each virus’s N protein (NR-9673 and
NR-12152; BEI Resources). The murine monoclonal antibody 9D5-1-1A
was used to detect CCHFVNprotein in infected cells. IFITM-1, IFITM-2,
and IFITM-3were immunostainedwith antibodies fromProteintechwith
catalog no. 11727-3-AP, 12769-1-AP, and 11714-1AP, respectively. IF-
ITM-2 and IFITM-3 antibodies cross-react and bind both IFITM-2 and -3
proteins but with reduced efficiencies. Mouse anti-Myc antibody (Sigma)
was used to detect Myc-tagged IFITMs. Alexa 488-conjugated goat anti-
mouse secondary antibody, Alexa 568-conjugated goat anti-rabbit anti-
body, or Alexa 647-conjugated goat anti-rabbit antibody (1:1,000; Life
Technologies) was used to visualize primary antibodies. Cell nuclei and
cytoplasmwere labeled with Hoechst 33342 (Life Technologies) andHCS
CellMask Red or Deep Red (Life Technologies) at a 1:10,000 dilution.
Confocal images were collected with a Leica TCS-SP5 confocal/multipho-
ton microscope. High-content quantitative imaging data were acquired
and analyzed on an Opera confocal reader (model 3842 [Quadruple Ex-
citation High Sensitivity {QEHS]} or model 5025; PerkinElmer) at two
exposures using a 10 air objective or 40 water objective. Analyses of
the images were accomplished within the Opera or Columbus environ-
ment using standard Acapella scripts.
RESULTS
RVFV infection is restricted by overexpression of IFITM-2 and
IFITM-3, but not by IFITM-1. Cell lines stably overexpressing
Myc-tagged IFITM-1, -2, or -3 or vector alone were generated in
Vero E6 cells as described previously (9). The expression of Myc-
tagged IFITM proteins in these cell lines was analyzed byWestern
blotting (Fig. 1A). In contrast to IFITM-1, IFITM-2 and IFITM-3
appeared as multiple bands and may represent the posttransla-
tionally modified forms of the protein reported by other groups
(16, 42). These cell lines were infected with RVFVMP-12 (Fig. 1B
and C), RVFV ZH501 (Fig. 1D and E), or Junín virus (Fig. 1F) at
different MOIs and for various durations of time. The extent of
infection was determined either by quantifying the percentage of
cells expressing viral protein using image-based analysis or by
plaque assay of the supernatants collected from virus-infected
cells. Both RVFV ZH501 infection and RVFV MP-12 infection
were restricted by IFITM-2 and IFITM-3, but not by IFITM-1
(Fig. 1B to E). IFITM-2- or -3-mediated restriction was relatively
profound in cells infected at a lowerMOI and at a specific window
of time during infection. At higher MOIs, less restriction was ob-
served, most likely because some infectious virions might have
escaped IFITM restriction. Similar observations were made by
plaque assay of the virus collected from the supernatants of RVFV-
infected cells (Fig. 1E). As a control, we also analyzed the infectiv-
ity of cells of the Vero E6 cell lines stably expressing IFITMs by
infectious Junín virus (Romero strain), an arenavirus that we pre-
dicted would not be restricted by IFITMs (Fig. 1F) because previ-
ous studies showed that retroviruses pseudotyped with entry pro-
teins of LASV or MACV were resistant to IFITM-mediated
restriction (9, 15). Similarly, our data showed that Junín virus was
resistant to IFITM-mediated restriction (Fig. 1F). More impor-
tantly, these data showed that IFITM-2 or -3 overexpression did
not change the properties of cells such that these cells resisted virus
replication nonspecifically. Furthermore, since both strains of
RVFV—ZH501 and MP-12—had similar phenotypes, we chose
to use MP-12 for the remaining studies.
Restriction of RVFV infection by IFITM-2 and -3 but not by
IFITM-1 extends to all cell types tested. Previous studies have
shown that VSIV, WNV, and DENV-1/2, similar to RVFV, were
restricted by IFITM-2 and -3 but not by IFITM-1 (10, 12). How-
ever, this pattern of restriction was cell type dependent. IFITM-2
and -3 restricted VSIV, WNV, and DENV-1/2 infections in all the
cell lines tested, while IFITM-1’s repressive effect was limited to
cell lines such as Vero E6, A549, or K562 and had no effect on cells
of the 293T cell line (8, 10–12). To test if the same applied toRVFV
infection, we generated 293T, HeLa, and A549 human cell lines
that stably overexpressed IFITM-1,-2, or -3 or vector alone and
subjected them to RVFV infection (Fig. 2). In all three cell lines,
similar to the results for Vero E6 cells (Fig. 1), IFITM-2 and -3 but
not IFITM-1 restricted RVFV infection, suggesting that the phe-
notype observed was not cell type dependent.
IFN- inhibits RVFV infection and induces IFITM gene ex-
pression in HeLa cells. RVFV infection is inhibited by type I IFN
(IFN-/) (1, 33, 34). We determined the sensitivity of the RVFV
MP-12 strain to type I IFN, as it was important to determine the
lowest MOI of RVFV and the shortest duration of infection re-
quired to achieve an infection rate greater than 50% inHeLa cells,
as IFITM-mediated viral restriction was the most profound in
cells incubated with lower MOIs for a specific duration of time
(Fig. 1). HeLa cells were treated with increasing concentrations of
IFN- or left untreated for 24 h and subsequently infected with
RVFV for another 24 h (Fig. 3A) or 48 h (Fig. 3B). Cells were then
fixed, stained with virus-specific antibodies, and subjected to
high-content quantitative image-based analysis to determine the
percentage of infected cells. Our results indicated that incubation
of RVFV at MOIs as low as 0.5 and 0.01 for periods of 24 h and 48
h, respectively, achieved an 80 to 100% infection rate inHeLa cells
(Fig. 3A and B). Treatment of HeLa cells with IFN- revealed a
concentration-dependent, potent inhibition of RVFV infection
(Fig. 3A and B). Concentrations as low as 5 U/ml of IFN- inhib-
IFITM Restricts RVFV
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ited RVFV infection by 50% (Fig. 3A and B), and the efficiency of
inhibition was dependent on theMOI. At the same dose of IFN-,
lower MOIs exhibited greater inhibition of infection. However,
MOIs lower than 0.01, such as 0.005, were associated with larger
variations. Consequently, experiments were limited to MOIs
above 0.01.
Furthermore, the level of induction of IFITM expression by
IFN- at its lowest dose (5 U/ml) that was sufficient to inhibit
FIG 1 IFITM-2 and IFITM-3 proteins restrict RVFV infection. (A) Western blot analysis of cells of Vero E6 cell lines stably expressing Myc-tagged IFITM-1,
IFITM-2, or IFITM-3 or vector alone. (B to F) Vero E6 cells stably expressing IFITM-1, -2, or -3 were infected with RVFV MP-12 (B and C), RVFV ZH501 (D
and E), or JUNV (F) at a specificMOI and for a specific duration of time, as indicated. The percentage of infected cells was determined by evaluating the number
of cells that expressed the viral protein GP for RVFV MP-12 infections (B and C), NP for RVFV ZH501 infections (D), or NP for JUNV infections (F).
Alternatively, the virus yields in culture medium samples harvested at 24 h postinfection with RVFV ZH501 were determined by plaque assay (E). All data (B to
F) are expressed asmeans standard deviations. (G) Representative images of Vero E6 cells stably expressing IFITM-1, IFITM-2, or IFITM-3 or the vector alone
that were infected with RVFV MP-12 at an MOI of 0.01 for 36 h and stained to detect the expression of GP (red) and nuclei (blue).
Mudhasani et al.
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RVFV infection by greater than 50% was determined (Fig. 3C to
F). HeLa cells were untreated or treated with 5 U/ml of IFN- for
various periods of time, followed by RNA extraction from cells to
evaluate IFITM expression by qRT-PCR. Alternatively, cells were
immunostained to detect IFITM expression at 24 h after IFN-
treatment. The images were acquired and subjected to high-con-
tent image-based analysis to determine the average fluorescent
intensities of IFITM expression. As expected, the qRT-PCR data
showed a time-dependent induction of IFITM-1, -2, and -3 ex-
pression under conditions of IFN- induction (Fig. 3C). IFITM-1
mRNA expression showed a higher degree of induction (4-fold)
than IFITM-2 (2-fold) or IFITM-3 (3-fold) mRNA expres-
sion. However, the high degree of induction could have been due
to the relatively very low levels of IFITM-1 mRNA expression
under basal conditions that were reflected in higher CT values
(data not shown). This observation was further supported by im-
munostaining data that showed very low to undetectable levels
of IFITM-1 under basal conditions compared to the levels of
IFITM-2 and -3 (Fig. 3D to F). Although IFN treatment induced
IFITM-1 expression, IFITM-1 levels remained low compared to
those of IFITM-2 or -3 (Fig. 3E). Similar observations were made
with IFITM antibodies from different vendors, suggesting that
these differences were not due to differences in the antibody affin-
ities (data not shown). For the rest of the study, HeLa cells were
used in the context of IFN- treatment to probe themechanismof
inhibition.
Depletion of IFITM-2 and IFITM-3, but not IFITM-1, en-
hances RVFV MP-12 infection. The optimized conditions de-
picted in Fig. 3A and B were applied to test how depletion of
IFITMproteins under basal conditions influences RVFV infection
of HeLa cells. To this end, HeLa cells were transfected with siRNA
targeting IFITM-1, -2, or -3 singly or in combinations consisting
of IFITM-2 and -3 or IFITM-1, -2, and -3. Forty-eight hours later,
cells were infected with RVFV at anMOI of 0.05 for a period of 28
h, 36 h, or 42 h. Subsequently, cells were fixed and stained for
high-content quantitative image-based analysis (Fig. 4A). Com-
paredwith cells transfectedwith nontargeting siRNA, the percent-
age of RVFV-infected HeLa cells increased upon depletion of
IFITM-2 or IFITM-3 (Fig. 4A). This increase became more pro-
nounced (by about 2-fold) when both IFITM-2 and -3 were de-
pleted together andwas similar to that when all IFITMs (IFITM-1,
-2, and -3) were depleted. Moreover, as shown in Fig. 4A, the
antiviral effects of IFITM-2 and -3 were profound at a specific
window of time (36 h) and were not detectable with longer virus
incubation (42 h). These findings further confirmed our earlier
observations that with time andwith increasing numbers of infec-
tious virus particles, the virus is able to overcome IFITM restric-
tion.
IFITM-2 and IFITM-3 mediate a large amount of the antivi-
ral activity of IFN- at lower levels. As IFN- induced IFITM
expression in HeLa cells (Fig. 3C to F), we tested whether a more
profound effect on RVFV MP-12 infection could be observed
upon depletion of IFITMs in IFN--treated cells. To this end,
HeLa cells were transfected with siRNA as described above (Fig.
4A), and on the following day, cells were either left untreated or
treated with increasing concentrations of IFN- (Fig. 4B and C).
At 24 h after IFN- treatment, cells were infected with RVFV for
42 h, fixed, and stained as described above. Consistent with our
previous observations, even low doses of IFN- (5 U/ml) potently
inhibited RVFV infection (Fig. 4B). Depletion of IFITM-2 or
IFITM-3 proteins alone or together enhanced infection of cells
compared to that for cells with IFITM-1 depletion or cells treated
with nontargeting siRNA, and this increase in infection rates was
more pronounced under IFN--induced conditions than under
IFN--uninduced conditions (Fig. 4B and C). Interestingly, al-
thoughhundreds of ISGs are induced by IFN, the antiviral effect of
IFN- at a lower dose of 5U/ml could bemitigated by almost 50%
by depleting IFITM-2 and -3 alone (compare the infection rates of
the corresponding siRNA-transfected cells for IFN--treated [5
U/ml] and untreated cells in Fig. 4B). Although the knockdown of
IFITM-2 and IFITM-3 increased infection by 6-fold at higher
IFN- doses (10 U/ml), it did not restore the infection rates to
those observed in cells not treatedwith IFN- (Fig. 4C), indicating
the overwhelming influence of other ISGs on RVFV infection at
higher IFN doses. Therefore, for the rest of this study, IFN- was
used at 5 U/ml in HeLa cells to evaluate IFITM-mediated restric-
tion of RVFV infection.
The target gene knockdown efficiency by siRNA treatment was
determined by qRT-PCR analysis (Fig. 4D) of cellular RNA that
was extracted from cells transfected with siRNA for 24 h and then
treated with IFN- (5 U/ml) for another 24 h. Our data show that
at the time of infection, the expression of the corresponding gene
was inhibited by greater than 90% at the level of mRNA in cells
transfected with siRNAs targeting IFITM-1, -2, or -3 or IFITM-2
and -3 simultaneously compared to the level of inhibition in cells
transfected with nontargeting siRNA.
Kinetics of GP and NP expression during one round of rep-
licationofRVFV.Todetermine the stage of the virus life cycle that
is restricted by IFITMs, we first characterized the kinetics and
localization of viral GP and NP expression during the course of
FIG 2 IFITM regulation of RVFV infection in multiple cell lines. (A to C) HeLa (A), A549 (B), or 293T (C) cells that stably overexpressed IFITM-1, IFITM-2,
or IFITM-3or vector alonewere generated and infected for 24 hwithRVFVZH501 at differentMOIs, as indicated. Cells were stainedwithNP antibody, following
which the images were acquired and the percentage of cells that stained positive for NP expression was determined by high-content quantitative image-based
analysis. Data are presented as the percentage of infected cells and are expressed as means standard deviations.
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RVFV infection (Fig. 5). HeLa cells were infected with RVFV for
various lengths of time (4, 6, 8, 10, or 12 h). Cells were then fixed,
permeabilized, and stained with RVFV NP- or GP-specific anti-
bodies to detect the expression of the corresponding viral proteins
(Fig. 5A and B). The virus egress from the cells was determined by
cell surface staining for GP to detect GP expressed on the cell
surface (S-GP) (Fig. 5B), for which the permeabilization step dur-
ing antibody staining was omitted. The percentage of cells that
expressed NP, GP, or S-GP was determined by high-content
quantitative image-based analysis (Fig. 5C and D). As shown in
Fig. 5A to C, viral NP expression reached a detectable level within
6 to 8 h postinfection, followed by GP expression at 8 to 10 h. Cell
surface expression of GP (S-GP), which corresponds to virus
egress, was observed at 10 to 12 h postinfection (Fig. 5B and C).
This was further confirmed by plaque assay of the virus collected
from cell culture supernatants (data not shown). Therefore, it
appears that one round of RVFV replication takes 10 to 12 h.
Interestingly, comparison of GP staining in permeabilized versus
nonpermeabilized cells suggested that cytoplasmic GP took about
2 h to appear on the cell surface (Fig. 5B to D). This observation
was made at all the different MOIs (MOI, 0.5, 1, 2.5, 5, 7.5, or 10)
that were tested (Fig. 5D).
IFITM-2 and IFITM-3 proteins do not interfere with viral
attachment or virion entry into cells. IFITMs restrict entry of
FIG 3 IFN- inhibits RVFV infection and induces IFITM expression. (A and B) HeLa cells were treated with the indicated concentrations of IFN- for 24 h,
followed by incubation with RVFVMP-12 for 24 h (A) or 48 h (B) at the indicatedMOI. Cells were immunostained to detect the expression of GP and subjected
to high-content quantitative image-based analysis to determine the number of cells that express GP. Data are presented as the percentage of infected cells and
expressed as the means  standard deviations. (C) HeLa cells induced with 5 U/ml of IFN- were harvested at the indicated time points, followed by RNA
extraction to determine the relative levels of IFITM-1, -2, and -3 gene expression compared with that under IFN--uninduced (0 h) conditions. qRT-PCR was
used to quantify the gene transcript levels, and all data were first normalized to those for the PPIB housekeeping gene and then normalized to those for the
corresponding gene transcript levels under IFN--untreated conditions. Data are representative of at least three independent experiments and are expressed as
the means standard deviations. (D to F) HeLa cells plated in 96-well plates were untreated or treated with 5 U/ml of IFN- for 12 h, following which the cells
were immunostained with the corresponding IFITM antibodies in the 488 channel (green), as indicated, and the images were subjected to high-content
quantitative image-based analysis to determine the mean fluorescence intensities. (D) Representative confocal images in which IFITMs are stained green and
nuclei are stained blue with Hoechst 33342. (E) The mean fluorescence intensities by IFITM staining in the green channel were calculated per well of a 96-well
plate and are replicates of 5 wells. (F) The data in panel Ewere normalized to the intensities of the corresponding genes under the IFN--untreated condition and
are presented as the fold induction.
Mudhasani et al.
8456 jvi.asm.org Journal of Virology
 
FLUAV, WNV, SARS-CoV, DENV-1/2, VSIV, HIV-1, MARV,
and EBOV (6, 12, 21, 23, 29, 43). However, during HIV-1 infec-
tion, IFITM-1 did not inhibit viral entry but restricted viral repli-
cation (13). In the absence of virus surrogates pseudotyped with
RVFV entry proteins, the role(s) of IFITMs in RVFV cell attach-
ment was analyzed by determining the amount of virus that asso-
ciated with host cells during the course of infection by qRT-PCR
analysis for viral RNA. Equal numbers of cells of each stable Vero
E6 cell line expressing IFITM-1, -2, or -3 or control cells were
plated at 100% confluence and incubated with RVFV for 5min or
1 h on ice to promote virion attachment to the cell surface in the
absence of endocytosis. Cells were washed extensively to remove
unbound virus, and viral RNA associated with the cells was ana-
lyzed by qRT-PCR (Fig. 6A). Our results demonstrated that there
was no significant difference in the amount of virus RNA that was
associated with control or IFITM-overexpressing cells.
By evaluating the time required for the virions to become re-
sistant to ammonium chloride, we further determined how fast
the virions, once attached to the cell surface, trafficked to endo-
somes to undergo membrane fusion. RVFV uncoating requires a
low endosomal pH (32). Ammonium chloride at a concentration
of 20mMraises the endosomal pH, thereby inhibiting virusmem-
brane fusion without causing overall cytotoxicity. Thus, Vero E6
cells were incubated with RVFV at 4°C for 30 min to allow virus
attachment but not internalization. Cells were then moved to a
37°C incubator, and 20 mM ammonium chloride was added over
a period of time. After 12 h, cells were fixed and stained for viral
GP expression. Within 30 min postattachment, about 50% of
RVFV virions were endocytosed and viral uncoating was accom-
plished. We concluded that RVFV endocytosis is completed
within 1 h postinfection, as more than 80% of RVFV virions be-
came insensitive to ammonium chloride after 1 h of incubation
(Fig. 6B).
This time course was used to assess if IFITMs regulate virion
endocytosis, as follows: Vero E6 cells stably expressing IFITMs or
control cells were incubated with virus at 4°C for 1 h and rapidly
moved to a 37°C incubator. At the indicated time points post-
transfer to incubation at 37°C (Fig. 6C), cells were treated with
trypsin and washed extensively to remove cell surface-bound vi-
rions. Viral RNA within cells was then determined by qRT-PCR
FIG 4 siRNA-mediated depletion of the IFITM-2 and IFITM-3 proteins enhances RVFV infection under basal and IFN--induced conditions. (A to D) HeLa
cells were transfected with siRNAs targeting IFITM-1, IFITM-2, IFITM-3, IFITM-2 and -3, IFITM-1, -2, and -3 (panel A only), or control nontargeting siRNA
(NS) and subjected to the following conditions. (A) At 48 h after siRNA transfection, cells were infected with RVFV at an MOI of 0.05 for a duration of 28 h, 36
h, or 42 h. Following infection, cells were fixed and immunostained to detect GP expression. The percentage of infected cells represents the percentage of
GP-expressing cells. (B) AN experiment similar to the one described for panel A, except that at 24 h after siRNA transfection, cells were washed and then left
untreated (0 U/ml) or treated with 5 or 10 U/ml of IFN- for 24 h, following which cells were washed and incubated with RVFV at anMOI of 0.01 for 42 h. (C)
The relative infection rate was calculated from the raw data in panel B by normalizing the infection rates for IFITM-depleted cells with those for the control
nontargeting siRNA-treated cells. (D) The level of IFITM gene knockdown upon siRNA treatment was determined in HeLa cells that were transfected with
siRNAs targeting the IFITM-1, -2, or -3 gene individually, both the IFITM-2 and -3 genes, or nontargeting siRNA for 24 h, followed by treatment with 5 U/ml
of IFN- for another 24 h. Relative gene expression levels were estimated first by normalizing the data to those for the internal PPIB housekeeping gene, followed
by normalizing the target gene levels to those for control nontargeting siRNA-treated cells. Data are presented as the means  standard deviations and are
representative of three independent experiments.
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analysis of the M segment of the viral genomic RNA. There was a
minimal increase in the amount of viral RNA within the cells as
time progressed during the first 4 h of infection. However, at later
time points, 6, 8, or 10 h postinfection, a gradual and significant
increase in viral RNA copy numberwas observed. Furthermore, at
these time points, IFITM-2- and -3-mediated restriction was ap-
parent. These data are in agreement with those from our NP ex-
pression kinetics studies (Fig. 5), in which RVFV NP expression
was observed starting at 6 h postinfection, suggesting that at this
time point viral transcription and replication are already under
way. Taken together, our results indicate that IFITM proteins do
not modulate virus attachment and internalization into cells.
Therefore, the differences in viral RNA levels aremost likely due to
reduced viral replication or inhibition of the release of viral RNA
from the endocytosed vesicles into the cytoplasm, where replica-
tion occurs.
IFITM-2 and IFITM-3 do not directly influence RVFV repli-
cation. On the basis of findings from previous studies of bunya-
viruses, RVFV genomic RNA replication occurs in the cytoplasm
of host cells after the endocytosed virion undergoes membrane
fusion to release the ribonucleoprotein complex (RNP) into the
cytoplasm (44). It is possible to compare the kinetics of viral rep-
lication if the number of RNPs released into the cytoplasm is the
same in control and IFITM-1-, -2-, or -3-expressing cells. This
can be achieved by increasing the MOI of virus used to infect
IFITM-2- or IFITM-3-overexpressing Vero E6 cells compared
with that of virus used to infect control cells to compensate for any
possible IFITM-2- or -3-mediated restriction that might occur
FIG 5 Kinetics of NP and GP expression during one round of replication of RVFV in HeLa cells. HeLa cells were incubated withMP-12 virus at anMOI of 5 (A
to C) or theMOI indicated in panel D for 4, 6, 8, 10, or 12 h. Infected cells were then fixed, permeabilized, and stained with RVFVGP- or NP-specific antibodies
to detect the expression of the corresponding viral proteins and counterstained with Hoechst 33342 to detect nuclei. To determine S-GP, the permeabilization
step during antibody staining was omitted. Images were acquired by confocal microscopy and subjected to high-content quantitative image-based analysis to
determine the percentage of cells expressing the corresponding viral proteins during the course of the infection. (A) Confocal images of NP- or GP-stainedHeLa
cells that were infected with RVFV at an MOI of 5 for the times indicated. In overlay images, NP is red, while GP is green. (B) Confocal images of HeLa cells
showing S-GP or total cellular GP. (C) Graphical representation of the percentage of cells expressing the corresponding viral proteins during the course of the
infection. (D) Graphical representation of HeLa cells incubated with MP-12 virus at the indicated MOI to determine the percentage of cells that express GP or
S-GP during the course of infection. All data shown here are representative of three independent experiments and are expressed as the means  standard
deviations.
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following viral internalization but prior to replication. To mea-
sure the replication kinetics in these different cells, we reasoned
that as viral RNA is packaged by NP, any changes in NP concen-
trations reflect the virus RNA replication status. Moreover, as
mentioned above, our data showed that amplification of viral
RNA andNP expression occurred at about the same time, at 6 to 8
h postinfection (compare Fig. 5C and 6C). Taking this into ac-
count, RVFV replication kinetics were analyzed by quantifying the
percentage of cells expressing NP during the course of infection.
At 6 h postinfection, we found that control or IFITM-1 cells in-
fected at an MOI of 0.5 yielded the same percentage of NP-ex-
pressing cells as IFITM-2- or IFITM-3-overexpressing cells in-
fected at an MOI of 1 (Fig. 7). Furthermore, as time progressed,
the percentage of NP-positive cells remained similar among these
populations of cells, suggesting no change in the kinetics of virus
replication (Fig. 7). Even when using the same MOI (0.5), the
increase in infection rate over time was similar in all cell lines
examined. From these data, we concluded that IFITM-2 or
IFITM-3 proteins do not inhibit infection at the viral replication
stage.
IFITM-2 and IFITM-3 restrict early stages of the RVFV life
cycle. IFITM gene expression levels at the time of virus entry into
the cell can be modulated by altering the IFN- exposure time.
Within 3 to 7 h of IFN- addition to HeLa cells, IFITM concen-
trations began to increase progressively for the duration of the
experiment (Fig. 3C). Furthermore, most of the RVFV virions
(50%) entered cells during the first 30 min following virus at-
tachment (Fig. 6B). Therefore, to determine the time window at
which elevated IFITM levels exert their antiviral activity over the
course of RVFV infection, we treated HeLa cells with IFN- at 24
h or 7 h prior to RVFV infection or at the time of virus addition to
cells (Fig. 8). IFN--untreated cells were used as a control. Cells
were also treatedwith siRNA targeting different IFITMsor control
nontargeting siRNAs to examine how knockdown of the different
IFITMs affected the RVFV infection rate under each of these
IFN- conditions. An MOI of 5 was used to achieve an infection
rate of approximately 50% at 12 h of infection. The percentage of
infected cells was monitored by quantifying the number of cells
that stained positively for GP expression at 12 h postinfection, as
this time span suffices for the virus to complete one replication
cycle. Consistent with our previous findings with IFN--un-
treated cells (Fig. 4A), cells depleted of IFITM-2 and IFITM-3 had
enhanced RVFV infection compared to control cells or cells de-
pleted of IFITM-1. Treating cells with IFN- for 24 h prior to
infection resulted in a 2-fold inhibition of RVFV infection (Fig.
8A), whichwas expected, as IFITMproteins reach high expression
levels at this time point (Fig. 3C). This inhibition wasmitigated to
a large extent by depleting IFITM-2 and IFITM-3. Interestingly, 7
h of IFN- pretreatment resulted in approximately 20% inhibi-
tion of infection compared to the level of inhibition for cells not
treated with IFN- (Fig. 8B) and produced a small mitigation of
this phenotype in IFITM-2- or -3-depleted cells (Fig. 8B). Finally,
treating cells with IFN- at the same time as virus incubation with
FIG 6 IFITM-2 or IFITM-3 proteins do not restrict MP-12 attachment to the cell surface or virus endocytosis. (A) Equal number of cells (5 105 cells/well in
a 6-well plate) of the Vero E6 cell line stably expressing IFITM-1, -2, or -3 or control vector were incubated without or with cold MP-12 virus at an MOI of 0.1
for 5 min or 1 h on ice. Cells were washed three times with PBS and subjected to RNA extraction and qRT-PCR analysis to detect the number of copies of viral
genomic RNA per 100 ng of RNA. Data are presented as the means standard deviations. (B) Vero E6 cells were seeded in 96-well plates (104 cells/well) and
cultured overnight. Cells were placed on ice and incubated withMP-12 virus at anMOI of 2 for 1 h. Unbound virus was washed off twice with cold PBS, and cells
were moved to 37°C. At the indicated time points, 20 mM ammonium chloride (NH4Cl) was added and left for 12 h; cells then were fixed and stained to detect
GP expression. Data presented show the percentage of GP-positive cells relative to the number of NH4Cl-untreated cells and are presented as the means 
standard deviations. (C) A continuation of the experiment whose results are presented in panel A, except that cells were incubated with virus at anMOI of 0.1 for
1 h on ice and then rapidly moved to 37°C. At the indicated time points, cells were trypsinized to remove surface-bound virus and then washed twice with PBS,
followed by RNA extraction. All data shown here are derived from replicates and are representative of three independent experiments.
FIG 7 IFITM proteins do not modulate replication kinetics of RVFV. Equal
numbers of cells (3 104 cells/well in a 12-well plate) of the Vero E6 cell line
stably expressing IFITM-1, -2, or -3 or empty vector were seeded overnight.
Cells were incubatedwith virus at anMOI of 0.5 (solid lines) or 1 (dotted lines)
for 1 h and washed to remove unbound virus, and the infection was allowed to
proceed for the indicated times. Cells were stained with NP antibody, follow-
ing which the images were acquired and the percentage of cells that stained
positive for NP expression was determined. Data are presented as the percent-
age of infected cells, are representative of three independent experiments, and
are the means standard deviations.
IFITM Restricts RVFV
August 2013 Volume 87 Number 15 jvi.asm.org 8459
 
cells had no effect on RVFV infection, which was the same as the
effect on cells not treated with IFN-. Together with our previous
data, these results suggest that IFITM-2 and -3 target early events
of the viral life cycle following viral internalization but prior to
viral replication.
Amajority of the IFITM-1 protein localizes to distinct com-
partments and does not localize with the IFITM-2 or -3 protein.
Different members of the IFITM family restricted viruses with
different efficiencies, and the efficiency of restriction was also de-
pendent on the cell line model used for infection. Although
IFITM-1 restricted EBOV,MARV, andHIV, it was dispensable for
RVFV infection (9, 11). It is possible that IFITM-1-coated vesicles
are not the sites of RVFV virion membrane fusion. To test this,
Vero E6 cells overexpressing Myc-tagged IFITM-1, IFITM-2,
IFITM-3, or vector alone were stained with antibodies against
Myc and IFITM-2 to detect the expression of exogenous Myc-
tagged IFITM-1, -2, or -3 and endogenous IFITM-2, respectively.
As shown in Fig. 9, a large fraction of IFITM-1 did not colocalize
with IFITM-2. Since the antibody against IFITM-2 cross-reacts
with IFITM-3, we could not distinguish IFITM-2 from IFITM-3
staining. Therefore, it is possible that RVFV is not restricted by
IFITM-1, as the compartments coated by IFITM-1may not be the
sites of virion uncoating.
Differences in thepatterns of expansionof the acidified com-
partments by different members of the IFITM family. As
shown in Fig. 9, Vero E6 cell lines stably overexpressing IFITMs
showed a large increase in the numbers of vesicular compartments
that were coated by IFITM proteins (as seen with the differential
interference contrast [DIC] image overlaid with the IFITM-
stained image). We further stained these compartments with two
different LysoTracker dyes that stained the acidified compart-
ments in the cell either red (Fig. 10A, top) or green (Fig. 10A,
bottom). We observed not only a large increase in the acidified
compartments, as shown previously with IFITM-3 (15), but also
striking differences in the size (Fig. 10B) and the number (Fig.
10C) of these vesicular compartments among the IFITM family
members. Interestingly, IFITM-1-overexpressing cells had large
vesicles, with some reaching the size of the nucleus. The same
pattern was also observed inHeLa, A549, and 293T cell lines over-
expressing IFITMs (data not shown). The large vesicles exhibited
a lower fluorescence intensity with LysoTracker dyes (below the
background threshold) andwere not recognized by the software as
vesicles; therefore, they were excluded from the vesicle number
and size analysis (Fig. 10B and C).
IFITMs exhibit broad-spectrum antiviral activity against
severalmembers of theBunyaviridae family.We further tested if
IFITMs can restrict infection by other members of the Bunyaviri-
dae family (Fig. 11). Bunyaviruses share similar virion morphol-
ogies with two envelope glycoproteins (Gn and Gc) that decorate
their surfaces and appear to use similar pH-dependent cell entry
pathways (30, 45–48). To examine if they also share sensitivity to
IFITMs, we tested the infectivity of LACV (genus Orthobunyavi-
rus), HTNV and ANDV (genus Hantavirus), and CCHFV (genus
Nairovirus) in Vero E6 cell lines that stably expressed vector or the
IFITM-1, -2, or -3 protein. With the exception of CCHFV, all
viruses tested were restricted by IFITMs (Fig. 11). In contrast to
RVFV, IFITM-1 was able to suppress LACV, HTNV, and ANDV
infection to the same extent as IFITM-2 or -3 (Fig. 11). Further
studies are warranted tomore broadly examine the role of IFITMs
in restriction of other viruses within the family Bunyaviridae.
DISCUSSION
The levels of IFITMs expression differ according to cell type and
cytokine environment and can strongly impact the spread of viral
infections (13). Using cells of different cell lines, including Vero
E6, HeLa, 293T, and A549, stably overexpressing IFITMs, we have
shown that IFITM-2 and IFITM-3, but not IFITM-1, restrict both
RVFV ZH501 and RVFV MP-12 (Fig. 1 and 2). Inhibition of in-
fection can be profound, particularly when cells are exposed to
relatively small amounts of virus (Fig. 1). IFITM inhibition may
therefore be important under natural infection conditions when
RVFV hosts are exposed to just a few infectious virions.
FIG 8 IFITM proteins do not influence RVFV infection after virus entry. (A) HeLa cells were transfected with siRNAs targeting IFITM-1, -2, or -3 individually,
IFITM-2 and -3 together, or nontargeting siRNA for 24 h, following which cells were not treated (No IFN-) or treated with 5 U/ml of IFN-, as indicated, for
24 h or 7 h prior to infection or at the time of infection (labeled 0 h). At 1 h postinfection, virus was washed off and the infection was allowed to proceed for 12
h, following which cells were fixed and immunostained to determine the percentage of cells expressing GP. Data are presented as the percentage of infected cells.
(B) Raw data on the percentage of infected cells (A) were used to calculate the percent increase in infection rates by IFN--induced IFITM proteins, as follows.
The increase in infection upon depletion of the IFITM-1, -2, or -3 protein individually or IFITM-2 and -3 proteins together was calculated by subtracting the
infection rate for cells treated with the respective siRNAs from the infection rate for control nontargeted siRNA (NS)-treated cells. The resulting value was
converted to the percent increase in infection rates by comparison with the average infection rate for nontargeted siRNA-treated cells. These values were
estimated for untreated and IFN--treated cells. The relative increase in the percentage of infection derived for IFN--untreated cells by each of the IFITM
proteins is due to basal expression levels; therefore, these values were subtracted from the corresponding values for each of the IFITM proteins that were treated
with IFN- to determine the contribution to the relative increase in infection rates induced by IFN-.
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We have focused on the sensitivity of RVFV to IFN- treat-
ment to determine the effect of IFITM depletion on RVFV infec-
tivity. The virus was sensitive to IFN- treatment at concentra-
tions as low as 5 U/ml (Fig. 3A and B). Under these conditions,
RVFV MP-12 infection was inhibited by greater than 70%. The
level of inhibition was dependent on both the MOI of the virus
and the duration of infection. Not only does IFN- exposure sup-
press virus replication in cells (33), but early studies also indicated
that human IFN- is effective in preventing viremia and fatal liver
damage in RVFV-infected rhesus monkeys (35, 49). Collectively,
these data suggest that RVFV has evolved to suppress IFN- pro-
duction but that it cannot counter the antiviral activities of the
downstream effectors of IFN-. Thus, RVFV serves as a very use-
ful model to explore the antiviral mechanisms of ISGs. Strikingly,
at low doses of IFN- (5 U/ml), siRNA-mediated depletion of
IFITM-2 and IFITM-3 alone mitigated the antiviral effect of
IFN- by 50% (Fig. 4A to C). It is possible that IFITMs are in-
duced and reach the threshold required to inhibit RVFV infection
rapidly at smaller doses of IFN- than other ISGs.
After we discovered the antiviral effects of IFITM-2 and -3 on
RVFV infection, we wanted to examine the stage(s) in the virus
replication cycle that is modulated by IFITMs. To this end, we
characterized the single replication cycle of RVFVMP-12, includ-
ing the expression of early and late viral proteins (NP and GP,
respectively) (Fig. 5), virion egress (Fig. 5), the kinetics of virion
entry (Fig. 6A and B), and viral RNA transcription/replication
(Fig. 6C and 7), with a combination of qRT-PCR and image-based
analyses. As RVFVMP-12 is widely used for molecular character-
ization of RVFV infection, including for the development of high-
throughput drug screening assays (50), the parameters deter-
mined should be useful to explore how infection modulators
influence specific stages of the RVFV life cycle.
Our data indicate that RVFV attachment to the cell surface
occurs rapidly and about 80% of the viral entry and uncoating
happens during the first hour postinfection (Fig. 6). A robust am-
plification of viral RNAwas observed at 4 to 6 h postinfection (Fig.
4C), followed by enhanced expression of viral NP and GP at 8 and
10 h, respectively (Fig. 5). One round of viral replication took
approximately 10 to 12 h. Application of these parameters to Vero
cells stably overexpressing IFITMs showed that infection inhibi-
tion mediated by IFITMs does not happen at the level of virion
attachment to cells (Fig. 6A) or entry into cells (Fig. 6C) but occurs
just before the initiation of viral RNA replication. This is because
we did not observe any change in the kinetics of viral RNA repli-
cation in control or IFITM-overexpressing cells (Fig. 7). More-
over, IFITM-2 and IFITM-3 modulate early events in the RVFV
replication cycle, as upregulation of IFITMs after viral entry had
no effect on virus infection (Fig. 8). Therefore, similar to the find-
ings for FLUAV, VSIV, andHIV-1, our data suggest that IFITM-2
and IFITM-3 might regulate RVFV membrane fusion by inhibit-
ing viral membrane fusion and release of RNPs into the cyto-
plasm.
Several lines of evidence had previously suggested that IFITMs
probably restrict viruses by inhibiting viral and endosomal mem-
brane fusion, thereby restricting RNP release into the cytoplasm.
First, studies with FLUAV and HIV-1 revealed that IFITM-3-
overexpressing cells inhibit release of virion cores from the endo-
some into the cytoplasm (11, 15). Second, IFITM restriction in
FIG 9 Amajority of IFITM-1 does not colocalize with IFITM-2 or -3. Confocal images of Vero E6 cells stably expressingMyc-tagged IFITM-1, -2, or -3 proteins
or vector alone that were stained withMyc antibody (red) or IFITM-2 antibody (green). DIC images were overlaid withMyc (red)-stained images to shows that
the large vesicles formed in these cells were coated by the corresponding IFITM protein. Bar, 10 m.
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WNV, DENV-1/2, and VSIV infection could be overcome by di-
rect transfection of genomic viral RNA into cells (10, 12). Third,
IFITMs restrict cathepsin-dependent entry of SARS-CoV into the
lysosome but do not restrict trypsin-induced fusion at or near the
plasma membrane (13). Collectively, these findings suggest that
IFITMs probably modulate virus-host membrane fusion steps.
The exact mechanism of this inhibition should be the focus of
future studies.
Our data provide clues to the antiviral activity of IFITMson the
basis of the localization of IFITMs and their influence on vesicular
compartments. Specifically, this study (Fig. 9 and 10) and previ-
ous reports have shown that IFITMs are largely localized to the
membranous regions of endosomes and lysosomes (9, 15, 16).
The membrane localization of IFITM-3 is critical for its antiviral
activity. For instance, it is known that localization of IFITM-3 to
endolysosomal fractions is positively regulated by S-palmitoyla-
tion and negatively by ubiquitinylation (16). IFITM-3 mutants
that cannot be palmitoylated or ubiquitinylated decrease or en-
hance the antiviral activity of IFITM-3, respectively, on the basis
of their ability to localize to endolysosomal compartments. Fur-
thermore, usingVero cells stably expressing IFITM-1, -2, or -3, we
showed a large increase in both the size and number of vesicular
compartments coated with IFITMs (Fig. 9 and 10). These data are
consistent with those from a recent studywhich showed that over-
expression of IFITM-3 alone increased Rab-5, Rab-7, and
LAMP-1 levels and the sizes of these compartments (15). It ap-
pears that IFITMsmodulate the biology of the vesicular compart-
ments that they occupy and probably influence virus trafficking.
Another interesting finding from this study is the unique pat-
tern of IFITM-mediated restriction, wherein IFITM-2 and -3 but
not IFITM-1 inhibited RVFV infection in all cell types tested, in-
cluding Vero E6 cells (Fig. 1) andHeLa, 293T, and A549 cells (Fig.
2). Previous reports have shown a similar pattern of IFITMrepres-
sion in VSIV, WNV, and DENV infection in some cell types, such
as 293T cells, but not in other cell types, such as Vero E6 or K562
cells (8, 10–12). In contrast, all three IFITMs restricted LACV,
HTNV, and ANDV (Fig. 11A to C), similar to the observations
made in HIV-1 (11), FLUAV (8), and MARV and EBOV (9) in-
fections. A potential explanation for the differences in IFITM vi-
rus inhibition may lie in the viral fusion proteins that regulate
virus-host membrane fusion and are categorized into three
classes. The Gc protein of bunyavirus mediates viral membrane
fusion and belongs to class II viral fusion proteins (51). Even
though theRVFVGc fusion protein shares structural featureswith
the LACV, HTNV, and ANDV Gc fusion proteins, RVFV is not
restricted by IFITM-1, while LACV,HTNV, andANDVare inhib-
ited by IFITM-1 (Fig. 11). This means that the type of fusion
protein may not be a critical parameter. The other possibility is
that IFITM-1 may not be present at the sites where RVFV virions
are undergoing fusion. Our data support this possibility, as we
observed that amajority of the IFITM-1 protein did not colocalize
with IFITM-2 or -3 proteins (Fig. 9). Our attempts to visualize
virions trapped inside IFITM-coated compartments were not suc-
cessful due to the large background of noninfectious virions. Our
future studies will focus on addressing these issues, which will
allow us to visualize and quantify virion entry and fusion. In ad-
FIG 10 Distinct pattern of expansion in acidified compartments by IFITM-2 or -3 compared to IFITM-1. (A) Vero E6 cells stably expressing Myc IFITM-1,
IFITM-2, or IFITM-3 or empty vector were stained with LysoTracker red DND-99 (LTRed; top) or LysoTracker green DND-26 (LTGreen; bottom) to visualize
the acidified compartments in the cells. Representative confocal images of LysoTracker red- or LysoTracker green-stained cells are shown. The image in each inset
is the enlarged version of the region pointed to by the arrows. Nuclei (blue) were stained with Hoechst 33342. (B and C) Five fields from each well of a 96-well
plate were acquired with an Opera high-content imager. The images were then exported to the Columbus database and analyzed with Acapella spot detection
algorithms to quantify the pixel (px) area (B) and number (C) of the acid compartments that were stained red, and the results are presented graphically. The
values represent the mean area or number per well standard error of the mean and are replicates of 12 wells.
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dition, marked differences in the ability to modulate vesicular
compartments in the cells were noted among the IFITMs. IFITM-
1-overexpressing cells formed very large vesicles (Fig. 9 and 10),
with some of them being as large as the nucleus. Most of the large
vesicles were not acid compartments, as they exhibited low fluo-
rescence intensities (below the background threshold) with Lyso-
Tracker dyes whose fluorescence intensity increases at low pH
(Fig. 10). In addition, IFITMswere able to expand acidic compart-
ments in the cells (Fig. 10), with IFITM-2 and IFITM-3 causing
the largest increases in the numbers and areas of acidic compart-
ments, respectively. Combining all these observations, we postu-
late that different members of the IFITMs localize to distinct
membrane regions, probably via binding to different cellular fac-
tors, and modify the membrane structure such that viral mem-
brane fusion is inhibited. This will be the subject of our future
studies.
In conclusion, the work presented here advances our under-
standing of RVFV infection and the antiviral activities of IFITM-2
and -3. Further studies focused on the properties of the IFITM-
coated vesicles that lead to degradation of endocytosed viruses
may provide additional information regarding the novel mecha-
nism(s) regulating virus membrane fusion and, hopefully, inspi-
ration for the development of new antiviral treatments.
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